



August 17, 2012

Patrick McLaughlin
Executive Director
Anaheim Clinical Trials
1085 N. Harbor Boulevard
Anaheim, CA 92801

RE: Lantu_L_05191

Dear Mr. McLaughlin:

This letter is in reference to the protocol sponsored by Sanofi noted above. The trial was officially closed at Dr. Winkle's site on 28JUN12. I was the monitor recently assigned to Dr. Winkle's site as we approached the conclusion of this study.

I am writing to advise you in reference to the performance of Anna Parker DCN, MS, RD, CDE, on this protocol. Anna was at all times professional and courteous. She was effective and efficient, responding to requests and initiating required actions at each step as we approached study closure. Anna's positive attitude and consistently quick response time during the Data Base Lock process was truly appreciated. Anna was a pleasure to work with during this study. I consider Anna an asset to your facility.

If you have any questions, please do not hesitate to contact me at: (619) 656-7858 or via email at nicholas.amalfitano@sanofi.com.

Sincerely,

A handwritten signature in blue ink, appearing to read "Nick Amalfitano", with a long horizontal flourish extending to the right.

Nick Amalfitano
Senior Regional Clinical Research Associate
sanofi US, Inc.
nicholas.amalfitano@sanofi.com
Tel: (619) 656-7858 - Fax: (908) 575-2479